Lilly’s Verzenio fails in KRAS-mutated lung cancerLilly’s Verzenio has failed to show benefits in lung cancer patients with a KRAS mutation, denting the company’s Share XLilly’s Verzenio fails in KRAS-mutated lung cancerhttps://pharmaphorum.com/news/verzenio-fails-lung-cancer/
